Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical breakthrough

EGFR T790M Inherited Lung Cancer Risk Study

Analysis based on 7 articles · First reported Sep 17, 2026 · Last updated Sep 22, 2026

Sentiment
5
Attention
2
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The study could expand the addressable market for genetic testing and lung cancer screening, benefiting diagnostics companies and potentially increasing demand for EGFR-targeted therapies. It may also prompt updated screening guidelines that include genetic risk factors, creating new opportunities for pharmaceutical and biotechnology firms focused on oncology.

healthcare biotechnology pharmaceuticals

A study published on Sept. 17, 2026 in Science identified the inherited EGFR T790M mutation as a major risk factor for lung cancer, especially in never-smokers. Researchers led by Jaclyn LoPiccolo and Pasi A. Jänne of Dana–Farber Cancer Institute, in partnership with 23andMe, analyzed genetic and health data from more than 3.37 million people of European ancestry. Carriers of the mutation had approximately 25 times higher odds of developing lung cancer overall, and never-smokers with the mutation had roughly 62 times higher risk. The mutation was found in about 1 in 15,850 individuals overall, but was substantially more common in the Southern Appalachian region of the United States, particularly Alabama, Mississippi, and Tennessee, where prevalence reached 1 in 2,078. The variant showed no significant association with other cancers or noncancerous lung conditions. The study suggests the mutation likely arose in Europe and was brought to the U.S. by British and Irish settlers during the colonial era. The findings may inform genetic testing and lung cancer screening guidelines, which currently focus on smoking history. A clinical trial is underway to evaluate CT-based screening in mutation carriers. The research also highlights existing EGFR-targeted therapies from AstraZeneca and Johnson & Johnson, and past development efforts by Boehringer Ingelheim and Hanmi Pharm.

40 AstraZeneca won FDA approval
30 Boehringer Ingelheim paid $730 million Hanmi Pharm
per
Jaclyn LoPiccolo is the lead researcher and corresponding author, playing a central role in the discovery and its communication.
Importance 90.0 Sentiment 0.0
stock
23andMe provided the large-scale genetic data essential for the study, demonstrating the value of its database for medical research and potentially boosting its business prospects.
Importance 85.0 Sentiment 15.0
per
Pasi A. Jänne is a senior researcher and corresponding author, contributing significantly to the study's design and interpretation.
Importance 85.0 Sentiment 0.0
cnt
The study focuses on U.S. populations, particularly the Southern Appalachian region, and may influence national screening guidelines and public health policy.
Importance 50.0 Sentiment 0.0
stock
AstraZeneca's Tagrisso is an EGFR-targeted therapy mentioned in the context of treating EGFR-mutated lung cancer; the study may increase awareness and demand for such therapies.
Importance 40.0 Sentiment 5.0
stock
Johnson & Johnson's Rybrevant is another EGFR-targeted therapy referenced; the study could support broader use of these treatments.
Importance 30.0 Sentiment 5.0
per
Stephen Chanock provided independent expert commentary, emphasizing the need for further research on screening protocols.
Importance 30.0 Sentiment 0.0
govactor
Stephen Chanock of the United States — National Cancer Institute provided expert commentary on the study's implications for screening and risk assessment.
Importance 25.0 Sentiment 0.0
per
Chris Amos offered independent expert opinion, highlighting the importance of genetic testing for families with a history of lung cancer.
Importance 25.0 Sentiment 0.0
priv
Boehringer Ingelheim's past deal with Hanmi Pharm for olmutinib is mentioned as a historical example of EGFR therapy development challenges.
Importance 20.0 Sentiment 0.0
stock
Hanmi Pharm's terminated licensing deal with Boehringer Ingelheim for olmutinib is referenced, highlighting past difficulties in EGFR drug development.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.